A citation-based method for searching scientific literature

Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
Times Cited: 191







List of co-cited articles
1522 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
405
66

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
281
58

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
342
58

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
241
57

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
163
50




The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
469
31

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
29


GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
229
23

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
224
22

In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
208
22

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
290
21

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
590
21

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
817
20

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
264
20


Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
321
19


Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees, Thomas Foltynie. Brain 2013
188
18

Insulin resistance impairs nigrostriatal dopamine function.
J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
93
19

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
579
18

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
255
18

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Lijun Cao, Dongfang Li, Peng Feng, Lin Li, Guo-Fang Xue, Guanglai Li, Christian Hölscher. Neuroreport 2016
50
36

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
53
33

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Peng Feng, Xiangjian Zhang, Dongfang Li, Chenhui Ji, Ziyue Yuan, Ruifang Wang, Guofang Xue, Guanglai Li, Christian Hölscher. Neuropharmacology 2018
54
33

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
17

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
I Moroo, T Yamada, H Makino, I Tooyama, P L McGeer, E G McGeer, K Hirayama. Acta Neuropathol 1994
116
17

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
A Hamilton, S Patterson, D Porter, V A Gault, C Holscher. J Neurosci Res 2011
152
17

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
233
17

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Chenhui Ji, Guo-Fang Xue, Cao Lijun, Peng Feng, Dongfang Li, Lin Li, Guanglai Li, Christian Hölscher. Brain Res 2016
62
27

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh, Jong-Sung Park, Seung-Hwan Kwon, Yong Joo Park, Senthilkumar S Karuppagounder, Hyejin Park,[...]. Nat Med 2018
415
17

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati, Yazhou Li, David Tweedie, Maja Mustapic, Sahil Chawla, Kashfia Chowdhury, Simon S Skene, Nigel H Greig,[...]. JAMA Neurol 2019
97
16

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
149
15



Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
138
15

Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.
Kristy M Heppner, Melissa Kirigiti, Anna Secher, Sarah Juel Paulsen, Rikley Buckingham, Charles Pyke, Lotte B Knudsen, Niels Vrang, Kevin L Grove. Endocrinology 2015
105
15

Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
494
15




Diabetes and the risk of developing Parkinson's disease in Denmark.
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth, Beate Ritz. Diabetes Care 2011
119
14



Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Henrik H Hansen, Katrine Fabricius, Pernille Barkholt, Jens D Mikkelsen, Jacob Jelsing, Charles Pyke, Lotte Bjerre Knudsen, Niels Vrang. Brain Res 2016
28
50

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
Yanwei Li, WeiZhen Liu, Lin Li, Christian Hölscher. Neuropharmacology 2016
51
27

A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jaishree Jalewa, Mohit Kumar Sharma, Simon Gengler, Christian Hölscher. Neuropharmacology 2017
46
30


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.